PsychonautWiki Archive

3-MeO-PCMo: Difference between revisions

← Older edit
>Josikins
>Blackhole
added important category
 
(22 intermediate revisions by 12 users not shown)
Line 1: Line 1:
{{SummarySheet}}
{{SubstanceBox/3-MeO-PCMo}}
{{SubstanceBox/3-MeO-PCMo}}
{|
|-
|-
| ''[[3-MeO-PCMo/Summary|Summary sheet: 3-MeO-PCMo]]''
|}
'''3-MeO-PCMo''' ('''4-[1-(3-methoxyphenyl)cyclohexyl]morpholine''') is a new morpholine analogue of [[3-MeO-PCP]]. It is a [[psychoactive class::dissociative]] [[NMDA receptor antagonist]], [https://en.wikipedia.org/wiki/Sigma_receptor sigma receptor]<ref>Sigma compounds derived from phencyclidine: identification of PRE-084, a new, selective sigma ligand (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/1658302</ref> and [[pain relief|anesthetic]] drug of the [[chemical class::arylcyclohexylamine]] chemical class with a potency of less than 1/10th of that of 3-MeO-PCP.


This compound induces a state referred to as "[[dissociative#subjective effects|dissociative anesthesia]]" when ingested and is therefore used as a recreational drug. 3-MeO-PCMo has recently become easily accessible  through online [[research chemical]] vendors<ref> (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/21215770https://www.ncbi.nlm.nih.gov/pubmed/21215770</ref> where it is being sold as a [[designer drug]].
'''3-MeO-PCMo''' ('''4-[1-(3-methoxyphenyl)cyclohexyl]morpholine''') is a new morpholine analogue of [[3-MeO-PCP]]. It is a [[psychoactive class::dissociative]] [[NMDA receptor antagonist]], [https://en.wikipedia.org/wiki/Sigma_receptor sigma receptor]<ref>{{cite journal | vauthors=((Su, T. P.)), ((Wu, X. Z.)), ((Cone, E. J.)), ((Shukla, K.)), ((Gund, T. M.)), ((Dodge, A. L.)), ((Parish, D. W.)) | journal=The Journal of Pharmacology and Experimental Therapeutics | title=Sigma compounds derived from phencyclidine: identification of PRE-084, a new, selective sigma ligand | volume=259 | issue=2 | pages=543–550 | date= November 1991 | issn=0022-3565}}</ref> agonist and [[pain relief|anesthetic]] drug of the [[chemical class::arylcyclohexylamine]] chemical class with a potency of less than 1/10th of that of 3-MeO-PCP.  


Although very little is known about this compound, similar morpholine analogues of [[phencyclidine]] have been researched before.<ref>Synthesis and determination of acute and chronic pain activities of 1-[1-(4-methylphenyl) (cyclohexyl)] morpholine as a new phencyclidine derivative in rats (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/21428243</ref><ref>Discriminable effects of phencyclidine analogs evaluated by multiple drug (PCP versus OTHER) discrimination training (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/2498947</ref>
This compound induces a state referred to as "[[dissociative#subjective effects|dissociative anesthesia]]" when ingested and is therefore used as a recreational drug. 3-MeO-PCMo has recently become easily accessible  through online [[research chemical]] vendors<ref>{{cite journal | vauthors=((Ahmadi, A.)), ((Khalili, M.)), ((Hajikhani, R.)), ((Naserbakht, M.)) | journal=Pharmacology, Biochemistry, and Behavior | title=New morpholine analogues of phencyclidine: chemical synthesis and pain perception in rats | volume=98 | issue=2 | pages=227–233 | date= April 2011 | issn=1873-5177 | doi=10.1016/j.pbb.2010.12.019}}</ref> where it is being sold as a [[designer drug]].
 
Although very little is known about this compound, similar morpholine analogues of [[phencyclidine]] have been researched before.<ref>{{cite journal | vauthors=((Ahmadi, A.)), ((Khalili, M.)), ((Hajikhani, R.)), ((Naserbakht, M.)) | journal=Arzneimittel-Forschung | title=Synthesis and determination of acute and chronic pain activities of 1-[1-(4-methylphenyl) (cyclohexyl)] morpholine as a new phencyclidine derivative in rats | volume=61 | issue=2 | pages=92–97 | date= 2011 | issn=0004-4172 | doi=10.1055/s-0031-1296173}}</ref><ref>{{cite journal | vauthors=((Overton, D. A.)), ((Shen, C. F.)), ((Ke, G. Y.)), ((Gazdick, L. P.)) | journal=Psychopharmacology | title=Discriminable effects of phencyclidine analogs evaluated by multiple drug (PCP versus OTHER) discrimination training | volume=97 | issue=4 | pages=514–520 | date= 1989 | issn=0033-3158 | doi=10.1007/BF00439557}}</ref>
==Chemistry==
==Chemistry==
[[File:Ach base.png|thumb|150px|right|Generic structure of arylcyclohexylamine molecule]]
[[File:Ach base.png|thumb|150px|right|Generic structure of arylcyclohexylamine molecule]]
Line 22: Line 19:
==Subjective effects==
==Subjective effects==
{{Preamble/SubjectiveEffects}}
{{Preamble/SubjectiveEffects}}
===Physical effects===
{{effects/base
|{{effects/physical|
*'''[[Effect::Nausea]]''' - It's worth noting that high dose 3-MeO-PCMo trips can sometimes result in nausea and vomiting at the peak of the trip. For most people, this is surprisingly not as unpleasant as they would initially expect due to the accompanying detachment from the physical senses.
*'''[[Effect::Nausea]]''' - It's worth noting that high dose 3-MeO-PCMo trips can sometimes result in nausea and vomiting at the peak of the trip. For most people, this is surprisingly not as unpleasant as they would initially expect due to the accompanying detachment from the physical senses.
*'''[[Effect::Motor control loss]]''' - A loss of gross and fine motor control alongside of balance and coordination is prevalent within 3-MeO-PCMo and becomes especially strong at higher doses. This means that one should be sitting down before the onset (unless experienced) in case of falling over and injuring oneself.
*'''[[Effect::Motor control loss]]''' - A loss of gross and fine motor control alongside of balance and coordination is prevalent within 3-MeO-PCMo and becomes especially strong at higher doses. This means that one should be sitting down before the onset (unless experienced) in case of falling over and injuring oneself.
*'''[[Effect::Perception of decreased weight]]''' - This creates the sensation that the body is floating and has become entirely weightless. This effect is strangely stimulating and encourages physical activities at low to moderate doses by making the body feel light and effortless to move.
*'''[[Effect::Perception of bodily lightness]]''' - This creates the sensation that the body is floating and has become entirely weightless. This effect is strangely stimulating and encourages physical activities at low to moderate doses by making the body feel light and effortless to move.
*'''[[Effect::Physical autonomy]]'''
*'''[[Effect::Physical autonomy]]'''
*'''[[Effect::Physical euphoria]]'''
*'''[[Effect::Physical euphoria]]'''
Line 33: Line 31:
*'''[[Effect::Tactile suppression]]'''
*'''[[Effect::Tactile suppression]]'''


===Cognitive effects===
}}
 
{{effects/visual|
====Suppression====
*'''[[Effect::Double vision]]''' - This component is prevalent at moderate to heavy doses and makes reading impossible unless one closes an eye.
*'''[[Effect::Frame rate suppression]]'''
*'''[[Effect::Pattern recognition suppression]]''' - This effect generally occurs at higher doses and makes one unable to recognize and interpret perceivable visual data.
*'''[[Effect::Visual acuity suppression]]'''
*'''[[Effect::Visual disconnection]]''' - This eventually results in the 3-MeO-PCMo equivalent of the famous "k-hole" or, more specifically, ''[[Visual disconnection#Holes, spaces and voids|holes, spaces and voids]]'' alongside of ''[[Visual disconnection#Structures|structures]]''.
 
====Distortions====
*'''[[Effect::Perspective distortions]]'''
 
====[[Effect::Geometry]]====
The visual geometry found within 3-MeO-PCMo can be described as very dark and bland when compared to that of [[ketamine]] or [[DXM]]. It often consists of many tiny interlocking and woven lines. It does not extend beyond level 4 geometry and can be comprehensively described through its [[Visual_effects:_Geometry#Variations|variations]] as simplistic in complexity, algorithmic in style, synthetic in feel, unstructured in organization, dimly lit in lighting, multicoloured in scheme, glossy in shading, soft in edges, small in size, slow in speed, smooth in motion, equal in rounded and angular corners, immersive in depth and consistent in intensity.
 
}}
 
|{{effects/cognitive|
The general head space of 3-MeO-PCMo is often described as simplistic and shallow in comparison to that of [[MXE]] and [[ketamine]]. The specific cognitive effects can be broken down into several separate subcomponents which are listed and described below:
The general head space of 3-MeO-PCMo is often described as simplistic and shallow in comparison to that of [[MXE]] and [[ketamine]]. The specific cognitive effects can be broken down into several separate subcomponents which are listed and described below:


===Cognitive effects===
*'''[[Effect::Amnesia]]'''
*'''[[Effect::Amnesia]]'''
*'''[[Effect::Anxiety suppression]]'''
*'''[[Effect::Anxiety suppression]]'''
Line 54: Line 69:
*'''[[Effect::Immersion enhancement]]'''
*'''[[Effect::Immersion enhancement]]'''
*'''[[Effect::Increased music appreciation]]'''
*'''[[Effect::Increased music appreciation]]'''
*'''[[Effect::Information processing suppression]]'''
*'''[[Effect::Analysis suppression]]'''
*'''[[Effect::Introspection]]'''
*'''[[Effect::Introspection]]'''
*'''[[Effect::Mania]]'''
*'''[[Effect::Mania]]'''
Line 60: Line 75:
*'''[[Effect::Thought deceleration]]'''
*'''[[Effect::Thought deceleration]]'''


===Visual effects===
}}
====Suppression====
*'''[[Effect::Double vision]]''' - This component is prevalent at moderate to heavy doses and makes reading impossible unless one closes an eye.
*'''[[Effect::Frame rate suppression]]'''
*'''[[Effect::Pattern recognition suppression]]''' - This effect generally occurs at higher doses and makes one unable to recognize and interpret perceivable visual data.
*'''[[Effect::Visual acuity suppression]]'''
*'''[[Effect::Visual disconnection]]''' - This eventually results in the 3-MeO-PCMo equivalent of the famous "k-hole" or, more specifically, ''[[Visual disconnection#Holes, spaces and voids|holes, spaces and voids]]'' alongside of ''[[Visual disconnection#Structures|structures]]''.
 
====Distortions====
*'''[[Effect::Perspective distortions]]'''
 
====[[Effect::Geometry]]====
The visual geometry found within 3-MeO-PCMo can be described as very dark and bland when compared to that of [[ketamine]] or [[DXM]]. It often consists of many tiny interlocking and woven lines. It does not extend beyond level 4 geometry and can be comprehensively described through its [[Visual_effects:_Geometry#Variations|variations]] as simplistic in complexity, algorithmic in style, synthetic in feel, unstructured in organization, dimly lit in lighting, multicoloured in scheme, glossy in shading, soft in edges, small in size, slow in speed, smooth in motion, equal in rounded and angular corners, immersive in depth and consistent in intensity.


===Auditory effects===
{{effects/auditory|
*'''[[Effect::Auditory suppression|Suppression]]'''
*'''[[Effect::Auditory suppression|Suppression]]'''
*'''[[Effect::Auditory distortion|Distortions]]'''
*'''[[Effect::Auditory distortion|Distortions]]'''
*'''[[Effect::Auditory hallucinations|Hallucinations]]'''
*'''[[Effect::Auditory hallucinations|Hallucinations]]'''
}}
}}
===Experience reports===
===Experience reports===
Anecdotal reports which describe the effects of this compound within this [[experience index]] include:
Anecdotal reports which describe the effects of this compound within this [[experience index]] include:
{{#ask:[[Category:3-MeO-PCMo]][[Category:Experience]]|format=ul|Columns=1}}
{{#ask:[[Category:3-MeO-PCMo]][[Category:Experience]]|format=ul|Columns=1}}
Additional experience reports can be found here:
* [https://www.erowid.org/experiences/subs/exp_3MeOPCMo.shtml Erowid Experience Vaults: 3-MeO-PCMo ]


==Potentially dangerous interactions==
==Potentially dangerous interactions==
Line 87: Line 95:


==Toxicity and harm potential==
==Toxicity and harm potential==
{{Further|Research chemicals#Toxicity and harm potential}}
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
The toxicity and long-term health effects of recreational 3-MeO-PCMo use do not seem to have been studied in any scientific context and the [[Toxicity::exact toxic dosage is unknown]]. This is because 3-MeO-PCMo has very little history of human usage. Anecdotal evidence from people who have tried 3-MeO-PCMo within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.  
The toxicity and long-term health effects of recreational 3-MeO-PCMo use do not seem to have been studied in any scientific context and the [[Toxicity::exact toxic dosage is unknown]]. This is because 3-MeO-PCMo has very little history of human usage. Anecdotal evidence from people who have tried 3-MeO-PCMo within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.  


It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this substance to ensure the administration of the intended dose.  
It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this substance to ensure the administration of the intended dose.
 
===Tolerance and addiction potential===
===Tolerance and addiction potential===
As with other NMDA receptor antagonists, the chronic use of 3-MeO-PCMo can be considered [[Addiction potential::moderately addictive with a high potential for abuse]] and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and [[withdrawal effects]] may occur if a person suddenly stops their usage.
As with other NMDA receptor antagonists, the chronic use of 3-MeO-PCMo can be considered [[Addiction potential::moderately addictive with a high potential for abuse]] and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and [[withdrawal effects]] may occur if a person suddenly stops their usage.


Tolerance to many of the effects of 3-MeO-PCMo [[Time to full tolerance::develops with prolonged and repeated use]]. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about [[Time to half tolerance::3 - 7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::1 - 2 weeks]] to be back at baseline (in the absence of further consumption). 3-MeO-PCMo presents cross-tolerance with [[Cross-tolerance::all [[dissociative]]s]], meaning that after the consumption of 3-MeO-PCMo all [[dissociative]]s will have a reduced effect.
Tolerance to many of the effects of 3-MeO-PCMo [[Time to full tolerance::develops with prolonged and repeated use]]. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about [[Time to half tolerance::3 - 7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::1 - 2 weeks]] to be back at baseline (in the absence of further consumption). 3-MeO-PCMo presents cross-tolerance with [[Cross-tolerance::all [[dissociative]]s]], meaning that after the consumption of 3-MeO-PCMo all [[dissociative]]s will have a reduced effect.
===Dangerous interactions===
{{DangerousInteractions/Intro}}
*'''[[Psychedelics]]''' - This combination is not advised because 3-MeO-PCE has been reported to cause extreme psychological disturbances such as [[psychosis]] and mania at a significantly higher rate than other [[dissociatives]].
{{DangerousInteractions/Dissos}}


===Urinary tract effects===
===Urinary tract effects===
Line 108: Line 122:
All of these, however, can easily be avoided by simply not using 3-MeO-PCMo on a daily or even weekly basis and manually limiting one's usage of the substance.
All of these, however, can easily be avoided by simply not using 3-MeO-PCMo on a daily or even weekly basis and manually limiting one's usage of the substance.


==Legal issues==
==Legal status==
{{legalStub}}
{{legalStub}}
3-MeO-PCMo is currently thought to be a legal grey area drug worldwide and is easily accessible  through the use of online [[research chemical]] vendors. However, this does not guarantee anyone to be immune from legal prosecution should they be found in possession of this substance as the legality is likely to vary from country to country.
3-MeO-PCMo is currently thought to be a legal grey area drug worldwide and is easily accessible  through the use of online [[research chemical]] vendors. However, this does not guarantee anyone to be immune from legal prosecution should they be found in possession of this substance as the legality is likely to vary from country to country.
*'''United Kingdom''' - It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.<ref>Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted</ref> While most arylcyclohexylamines are covered by a generic clause<ref>The Misuse of Drugs Act 1971 (Amendment) Order 2013 (Legislation.gov.uk) | http://www.legislation.gov.uk/uksi/2013/239/introduction/made</ref>, the 1-morpholine group of 3-MeO-PCMo is outside of the definition. While the drug is still controlled under the Psychoactive Substances Act, simple possession (other than within a custodial institution) is not criminalised.
*'''Germany:''' 3-MeO-PCMo is controlled under the NpSG (''New Psychoactive Substances Act'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref> as of July 18, 2019.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl119s1083.pdf|title=Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27|pages=1083-1094|publication-date=July 17, 2019|access-date=January 1, 2020|language=de}}</ref> Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref>
*'''Switzerland:''' 3-MeO-PCMo is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''United Kingdom''' - It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.<ref>{{Citation | title=Psychoactive Substances Act 2016 | url=https://www.legislation.gov.uk/ukpga/2016/2/contents/enacted}}</ref> While most arylcyclohexylamines are covered by a generic clause<ref>{{Citation | title=The Misuse of Drugs Act 1971 (Amendment) Order 2013 | url=https://www.legislation.gov.uk/uksi/2013/239/introduction/made}}</ref>, the 1-morpholine group of 3-MeO-PCMo is outside of the definition. While the drug is still controlled under the Psychoactive Substances Act, simple possession (other than within a custodial institution) is not criminalised.


==See also==
==See also==
Line 120: Line 137:
*[[Methoxetamine]]
*[[Methoxetamine]]
==External links==
==External links==
*[https://en.wikipedia.org/wiki/3-MeO-PCMo 3-MeO-PCMo (Wikipedia)]
*[[wikipedia:3-MeO-PCMo|3-MeO-PCMo (Wikipedia)]]
*[http://drugs.tripsit.me/3-meo-pcmo 3-MeO-PCMo (TripSit)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=970 3-MeO-PCMo (Isomer Design)]
*[https://www.ukchemicalresearch.org/Thread-3-MeO-PCMo 3-MeO-PCMo (UK Chemical Research)]
*[https://www.ukchemicalresearch.org/Thread-3-MeO-PCMo 3-MeO-PCMo (UK Chemical Research)]
*[http://www.bluelight.org/vb/threads/758083-Novel-dissociative-3-MeO-PCMo 3-MeO-PCMo (Bluelight)]
*[http://www.bluelight.org/vb/threads/758083-Novel-dissociative-3-MeO-PCMo 3-MeO-PCMo (Bluelight)]


==References==
==References==
<references/>
<references />
 
[[Category:Psychoactive substance]]
[[Category:Psychoactive substance]]
[[Category:Arylcyclohexylamine]]
[[Category:Arylcyclohexylamine]]
[[Category:Dissociative]]
[[Category:Dissociative]]
[[Category:Substance]]
[[Category:Research chemical]]
 
{{#set:Featured=true}}
{{#set:Featured=true}}
Retrieved from "http://psy.st/wiki/3-MeO-PCMo"